CytoDyn Inc. Annual report [Section 13 and 15(d), not S-K Item 405]

Annual report [Section 13 and 15(d), not S-K Item 405]

Income (loss) per Common Share (Tables)

Income (loss) per Common Share (Tables)

12 Months Ended

May 31, 2025

Income (loss) per Common Share

Schedule of reconciliation of the numerators and denominators of basic and diluted net (loss) income per share


		Years ended May 31,
(in thousands, except per share amounts)		2025			2024
Numerator:
Net income (loss)		$	3,745		$	(49,841)
Less: Accrued preferred stock dividends			(1,483)			(1,483)
Net income (loss) applicable to common stockholders		$	2,261		$	(51,324)
Denominator:
Basic weighted average common shares outstanding			1,205,755			969,509
Effect of dilutive securities:
Warrant exercises			34,821			—
Option exercises			2,346			—
Diluted weighted average common shares outstanding			1,242,922			969,509

Basic income (loss) per share			0.00			(0.05)
Diluted income (loss) per share			0.00			(0.05)

Schedule of securities excluded from computation of earnings per share


	Years ended, May 31
(in thousands)	2025		2024
Stock options, PSUs, and warrants	217,785		387,294
Convertible notes	12,000		12,000
Convertible preferred stock	40,013		37,046